Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers

Breast Cancer

Volumn 21, Issue 1, 2014, Pages 52-57

  Murase, Keiko ^a   Yanai, Ayako ^a   Saito, Masaru ^a   Imamura, Michiko ^a   Miyagawa, Yoshimasa ^a   Takatsuka, Yuichi ^a   Inoue, Natsuko ^a   Ito, Takashi ^a   Hirota, Seiichi ^a   Sasa, Mitsunori ^b   Katagiri, Toyomasa ^c   Fujimoto, Yasuhisa ^d   Hatada, Takuya ^e   Ichii, Shigetoshi ^f   Nishizaki, Tomoyuki ^a   Tomita, Naohiro ^a   Miyoshi, Yasuo ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Tokushima Breast Care Clinic   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d Tachibana Hospital   (Japan)

^e Uminosato Clinic   (Japan)

^f Konan Hospital Foundation Rokko Island Hospital   (Japan)

Author keywords

Breast cancer; Ki67; Luminal subtype

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HER2 NEGATIVE BREAST CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84891557388     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0348-z     Document Type: Article

References (11)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
2. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-50.
3. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-47.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
5. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol. 2003;17:575-88. Erratum in: Mol Endocrinol. 2003;17:1892
6. Sakamoto G, Inaji H, Akiyama F, Haga S, Hiraoka M, Inai K, et al. Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer. 2005;12(Suppl):S1-27.
7. Yamashita H, Iwase H, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, et al. Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis. Ann Oncol. 2011;22:1318-25.
8. Haynes BP, Straume AH, Geisler J, A'Hern R, Helle H, Smith IE, et al. Intratumoral estrogen disposition in breast cancer. Clinical Cancer Res. 2010;16:1790-801.
9. Brodie A, Sabnis G, Jelovac D. Aromatase and breast cancer. J Steroid Biochem Mol Biol. 2006;102:97-102.
10. Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AM. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 2008;68:4518-24.
11. Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, et al. Estrogen insensitivity in a model of estrogen receptor-positive breast cancer lymph node metastasis. Cancer Res. 2007;67:10582-91.